

What is claimed is:

1. Use of an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R) in the manufacture of at least one medicament for treating moderate-to-severe asthma in a patient, wherein the antibody or antigen binding fragment thereof comprises a heavy chain comprising heavy chain complementarity determining region (HCDR) sequences of SEQ ID NOs:148, 150, and 152, and a light chain comprising light chain complementarity determining region (LCDR) sequences of SEQ ID NOs:156, 158, and 160.
2. The use according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR)/light chain variable region (LCVR) sequence pair of SEQ ID NOs: 162/164.
3. The use according to claim 1 or 2, wherein the at least one medicament is formulated for administration to the patient in a dosing regimen that provides a therapeutically effective amount of the antibody or antigen-binding fragment thereof as one or more initial doses followed by one or more secondary doses of the medicament.
4. The use according to any one of claims 1 to 3, wherein the medicament is formulated for administration to the patient systemically, subcutaneously, intravenously, or intranasally.
5. The use according to claim 3 or 4, wherein a dose is 75 to 600 mg of said antibody or antigen-binding fragment thereof.
6. The use according to any one of the claims 3 to 5, wherein each initial dose or each secondary dose is formulated for administration every two weeks.
7. The use according to any one of claims 4 to 6, wherein the medicament is formulated for administration to the patient subcutaneously.
8. The use according to any one of claims 1 to 7, wherein said medicament is formulated for administration with an inhaled corticosteroids (ICS) or a long-acting beta-agonist (LABA).
9. The use according to claim 8, wherein said use is for reducing dependence on the inhaled corticosteroids (ICS) and/or the long-acting beta-agonists (LABA).

10. The use according to any one of claims 1 to 9, wherein said use is for improving lung function.

11. The use according to any one of claims 1 to 10, wherein treating moderate-to-severe asthma is an add-on treatment.